Gilead Sciences’ (GILD) “Hold” Rating Reiterated at BMO Capital Markets

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by stock analysts at BMO Capital Markets in a research note issued on Wednesday.

The analysts wrote, “Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars.””

Several other equities research analysts have also commented on GILD. Mizuho set a $83.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday. Leerink Swann cut their price target on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday. Bank of America lifted their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday. Morgan Stanley cut their price target on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $85.58.

Shares of Gilead Sciences (NASDAQ:GILD) traded up $2.38 on Wednesday, hitting $82.76. 20,172,534 shares of the stock were exchanged, compared to its average volume of 8,810,000. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The firm has a market cap of $108,080.00, a price-to-earnings ratio of 9.42, a price-to-earnings-growth ratio of -1.73 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the business earned $2.70 EPS. The company’s revenue was down 18.7% on a year-over-year basis. equities research analysts expect that Gilead Sciences will post 8.53 EPS for the current year.

In other news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 578,333 shares of company stock worth $44,100,508. Insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Welch Investments LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the period. Hedge funds and other institutional investors own 75.84% of the company’s stock.

WARNING: “Gilead Sciences’ (GILD) “Hold” Rating Reiterated at BMO Capital Markets” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/07/gilead-sciences-gild-hold-rating-reiterated-at-bmo-capital-markets.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply